An online submission and tracking service
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The principal/corresponding author will be required to submit a copyright letter along with the manuscript, on behalf of all the co-authors (if any) to confirm that the manuscript (or any part of it) has not been published previously or is not under consideration for publication elsewhere. Furthermore, any illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. The figures from patent documents are freely available on the databases and may not require any permission unless stated otherwise.
For all online submissions, please provide soft copies of all the materials (main text in MS Word or Tex/LaTeX), figures/illustrations in TIFF, PDF or JPEG, and chemical structures drawn in ChemDraw (CDX)/ISISDraw (TGF) as separate files, while a PDF version of the entire manuscript must also be included, embedded with all the figures/illustrations/tables/chemical structures
It is imperative that before submission, the author(s) should carefully proofread the files for special characters, mathematical symbols, Greek letters, equations, tables, references and images to ensure that they appear in proper format.
References, figures, tables, chemical structures
A successful electronic submission of the manuscript will be confirmed by a system-generated email acknowledgement to the principal/corresponding author immediately. Any queries therein should be addressed at [email protected]
The editorial policies of Bentham Science Publishers on publication ethics, peer-review, plagiarism, copyrights/licenses, errata/corrections and article retraction/withdrawal can be viewed at Editorial Policy
The journal publishes peer-reviewed mini- and full-length review and research articles written in English. Thematic Issues edited by invited Guest Editors are also considered for publication.
For the submission of research articles, the author should have already filed a patent with a leading patent authority and it should be registered. Secondly, the author should not have published any research paper on the intellectual property of that patent.
These special issues are peer-reviewed and may contain invited or uninvited review/mini-review articles or a mixture of research articles, and reviews/mini-reviews. A single topic issue will offer a short perspective and co-ordinate the solicitation of manuscripts between 3-5 (for a mini-thematic issue) to 6-10 (for full-length thematic issue) from leading scientists. Authors interested in editing a single topic in an emerging topic of outstanding developments in biomarker research and discovery may submit their proposal to the Executive Editor at [email protected] or [email protected] for consideration.
For proposals to publish conference proceedings in this journal, please contact us at email: [email protected]
A separate section of important and recent patents on biomarkers is also included in the journal. The patents annotated in this section are relevant to the articles published in this journal issue, categorized in fast emerging patent biomarker applications
Research articles should be 4000-8000 words excluding figures, structures, photographs, schemes, tables
Mini-reviews should be 3000-6000 words excluding figures, structures, photographs, schemes, tables
Full-length reviews should be 8000-40000 words excluding figures, structures, photographs, schemes, tables
There is no restriction on the number of figures, tables or additional files
The manuscript should be written in English in a clear, direct and active style. All pages must be numbered sequentially, facilitating in the reviewing and editing of the manuscript. For further convenience, our contracted service provider Eureka Science can provide assistance to authors for the preparation of manuscripts.
Manuscripts may be divided into the following sections:
Authors who publish in Bentham Science print & online journals will transfer copyright to their work to Bentham Science Publishers. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication. Once submitted to the journal, the author will not withdraw their manuscript at any stage prior to publication.
It is mandatory that a signed copyright letter also be submitted along with the manuscript by the author to whom correspondence is to be addressed. The article should not contain any such material or information that may be unlawful, defamatory, fabricated, plagiarized, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the copyright agreement. Copyright letter can be downloaded from the journal's Web site. Download the Copyright letter.
The title of the article should be precise and brief and must not be more than 120 characters. Authors should avoid the use of non-standard abbreviations. The title must be written in title case except for articles, conjunctions and prepositions. Tilte, running title, byline, correspondent footnote and keywords should be written as presented in original manuscript.
Authors must provide a short ‘running title’ of their manuscripts.
The names of the authors should be provided according to the previous citations or as the authors would want them to be published along with the institutional affiliations, current address, telephone, cell & fax numbers and the email address. Email address must be provided with an asterisk in front of the name of the principal author. The corresponding author should also be designated and the full address, telephone, cell & fax numbers and the email address must be stated to receive correspondence and galley proofs.
The abstract of an article should be its clear, concise and accurate summary, having no more than 250 words, and including the explicit sub-headings (as in-line or run-in headings in bold) and must include information regarding patents. Use of abbreviations should be avoided and the references should not be cited in the abstract. Ideally, each abstract should include the following sub-headings, but these may vary according to requirements of the article.
Background
Objective
Method
Results
Conclusion
A graphic must be included with each manuscript for use in the Table of Contents (TOC). This must be submitted separately as an electronic file (preferred file types are EPS, PDF, TIFF, Microsoft Word, PowerPoint and CDX
Graphical Abstracts should be submitted as a separate file (must clearly mention graphical abstract within the file) online
6 to 8 keywords must be provided.
The main text should begin on a separate page and should be divided into title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed, which should be followed by the Acknowledgements and Reference sections. The Review Article should mention any previous important, recent and old reviews in the field and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments along with relevant patents. The authors should avoid presenting material which has already been published in a previous review. The authors are advised to present and discuss their observations in brief.
For Research Articles, the manuscript should begin with the title page and abstract followed by the main text, which must be structured into separate sections as
All clinical investigations must be conducted according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee is required. For research involving animals, the authors should indicate whether the procedures followed were in accordance with the standards set forth in the eighth edition of Guide for the Care and Use of Laboratory Animals (grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf/; published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).
A specific declaration of such approval must be made in the copyright letter and in a stand-alone paragraph at the end of the Methods section especially in the case of human studies where inclusion of a statement regarding obtaining the written informed consent from each subject or subject's guardian is a must. The original should be retained by the guarantor or corresponding author. Editors may request to provide the original forms by fax or email.
Authors should review the most recent and important patents based on the topic covered. Coverage of biomarkers in basic, medical, environmental, and pharmaceutical research should be emphasized including the significance of reported patents.
The review/research article should conclude with a short section called “Current & Future Developments”. The author(s) will give their opinion on the current and future important developments on the topic discussed in their article.
Greek symbols and special characters often undergo formatting changes and get corrupted or lost during preparation of a manuscript for publication. To ensure that all special characters used are embedded in the text, these special characters should be inserted as a symbol but should not be a result of any format styling (Symbol font face) otherwise they will be lost during the conversion to PDF/XML.
Authors are encouraged to consult reporting guidelines. These guidelines provide a set of recommendations comprising a list of items relevant to their specific research design.
Only ISO symbols, written in italic, should be used for the various parameters. All kinds of measurements should be reported only in International System of Units (SI). SI units should always be written in Roman and separated from the numerical value by a space (whatever the language).
The µ in µg or µm should be in Roman. The symbol for litre is L and that for minute is min. For temperature, please use only one of °C, °F or K in the entire manuscript. As the Angström (1Å = 10-10m) is not an SI unit, it should be replaced by the nanometre (1nm = 10-9m) or by the picometer (1pm = 10-12m): 1Å = 0.1nm = 100pm. Multiple units should be written with negative superscripts (for example, 25mgµL-1µs-1). The list of notations should appear just before the first paragraph of full text.
A list of symbols and units should be provided if used extensively throughout the text.
A small paragraph summarizing the contents of the article, presenting the final outcome of the research or proposing further study on the subject, may be given at the end of the article under the Conclusion section.
If abbreviations are used in the text either they should be defined in the text where first used, or a list of abbreviations can be provided.
All potential conflicts of interest (competing interests) that could have a direct or indirect influence on the work must be disclosed by the authors. Even if an author does not have a conflict, disclosing affiliations and interests allows for a more comprehensive and open approach, which leads to a more accurate and objective evaluation of the work. Conflicts of interest, whether genuine or imagined, are a perspective to which the readers are entitled.
The publication of a conflict statement in the article itself, as well as the submission of the conflict disclosure form, is required for all types of papers. It is not necessarily the case that a monetary relationship with examination support or funding for counseling work is inappropriate. Even if the authors do not have any conflict of interest, they still need to provide a confirmation statement in their manuscripts, i.e., “The author(s) confirm(s) that there is no conflict of interest related to the manuscript.”
The following are some examples of potential conflicts of interest that are directly or indirectly related to the research:
Type of support/grant number
Institutional Conflicts of Interest
Funds received by the author
Funds received by the institution
Travel allowances for the research
Funds received for article preparation and reviewing
Funds for conducting review activities
Support provided for article writing assistance, for drugs, equipment, etc
Paid lectures
Pending fund or grant
Financial conflicts of interest can be personal as well as institutional. Personal conflict of interest occurs when a contributor involved in the publication process either receives an amount of money or expects to receive some financial help (including any other financial benefits such as patents or stocks, gifts or services) that may impact the work related to a specific publication. More importantly, in academic research, such financial relationships can lead to institutional conflicts of interest (COIs) because the economic interests of the institution or institutional representatives may unsuitably affect the decision-making process.
An institutional conflict of interest arises in a situation when financial interests of an institution or any institutional official (e.g., investments held by the university in a company) have the potential to unduly influence the research conducted by its employees or students, or pose an unacceptable risk to human subjects. Such conflicts usually arise in a state of affairs where a research project directly offers assistance or a benefit to an external entity via evaluation, validation, trial or test of an invention, product, drug, service or technology, and the institution holds a financial interest with the external entity. Such financial interests incorporate, but are not limited to, receipt of licensing payments or royalties from the external entity, or ownership interest with the external entity. When human subjects are involved in any research project, and the institution supports such a financial interest, the conflict of interest is speculated to be unreasonable.
In addition, interests other than monetary and any funding (non-financial interests) should be declared if they are relevant to readers. Personal relationships or conflicting interests directly or indirectly related to research, as well as professional interests or personal opinions that may impact your research, are examples of these.
Intellectual property, in basic terms, refers to any intangible property that is the result of creativity, such as patents, copyrights, etc. Similarly, this section seeks to know about copyright and patent (licensed patent, pending or issued) and any payment received for intellectual property, such as:
Patent
Licensed Patent
Issued Patent
Pending Patent
Royalties
Licensee
Remarks
All conflict of interest disclosure forms are collected by the corresponding author. It is sufficient for the corresponding author to sign the disclosure form on behalf of all authors in author collaborations when legal agreements for representation allow it. The templates of the form can be found here.
Before the reference list, the corresponding author will include a summary statement in the text of the article that reflects what is reported in the potential conflict of interest disclosure form (s). Author(s) may declare(s) names of reviewers who they think might have a potential conflict of interest; therefore, Editorial Office could avoid inviting such reviewers for an unbiased opinion.
Undisclosed conflict of interest cases before or after the publication of an article are dealt with as per the guidelines of COPE.
Undisclosed conflict of interest in a submitted article (View COPE guidelines)
Undisclosed conflict of interest in a published article (View COPE guidelines)
For more information on COIs, see the guidance from the ICMJE.
Bentham Science tries to conduct a transparent peer-review process with the help of the reviewers who do not have any conflict of interest with the authors. In this connection, reviewers who belong to the same institute or countries as authors are not invited to review manuscripts. However, it is not possible for the Editorial Office to be aware of all competing interests; therefore, it is expected from authors to submit:
List of reviewers who they think have a conflict of interest to ensure a transparent and unbiased review process.
The Editorial Office expects reviewers:
Not to accept manuscript review requests if they have any potential conflict of interest and inform the Editorial Office accordingly.
To decline review requests if they have recently published or submitted an article with any of the authors listed in the manuscript.
To inform the Editorial Office if they have any personal relationship with the authors or work in the same institutes as of authors, which could affect the review transparency.
To abstain from reviewing and informing the Editorial Office/Editor-in-Chief/Handling Editors about any scientific misconduct or fraud, plagiarism, conflict of interest, or any other unethical behavior related to the manuscript, which they found while reviewing it.
During the submission of review comments, reviewers are asked to reconfirm that they do not have any conflict of interest related to the article. After confirming the below statement, they can submit their comments.
“I hereby confirm that I don’t have any conflict of interest related to the manuscript.”
If, however, there are still any remaining interests, then reviewers must mention those in the ‘Confidential’ section of the review form.
Reviewers are not encouraged to contact authors directly regarding any of their conflicts of interest. Peer reviewers should follow journals’ policies in situations they consider to represent a conflict to reviewing.
If reviewers intentionally undisclosed any conflict of interest, then they will be blacklisted for any future peer reviewing activity of the journal.
The Editorial Office always ensures that an author, if added after peer review activity of a manuscript, is not part of the reviewers’ list who have conducted a peer review of the same manuscript.
Editors must not review submitted manuscripts if they have any personal, professional or financial involvement/conflict of interest with the authors of the manuscript. Every participant involved in the peer review process, including editorial board members, reviewers, and editors, must declare any potential conflicts of interest to ensure a transparent and unbiased review activity.
Editors-in-Chief or Editors who are responsible for the initial and final decision should recuse themselves to review or take decisions on any manuscript that is written by authors affiliated to the same institute as of editor, or if they have been a family member, competitor, collaborator, or have published any manuscript in last 3 years with the authors associated with the manuscript. They can however nominate someone else on the Board who could provide a neutral opinion on the manuscript.
The Editorial office recommends editors to follow COPE and WAME guidelines to process such manuscripts which involves their personal relationship.
The initial and final decision on the manuscripts submitted by an Editor/Editor-in-Chief will be taken by any other member of the Board. The Editorial Office will identify members who do not have any potential conflict of interest with the Editor or Editor-in-Chief.
References should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section. All references must be complete and accurate. Date of access should be provided for online citations Journal names should be abbreviated according to the Index Medicus/MEDLINE. It is necessary to list all authors if the total number of authors is 6 or less and for more than 6 authors use 6 authors and then
References should be listed in the following Vancouver Style:
Arisi I, D'Onofrio M, Brandi R, Felsani A, Capsoni S, Drovandi G,
Lundblad RL . Development and Application of Biomarkers. 1st ed. Boca Raton: Florida 2011.
Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. In: Schnellmann RG Eds. Comprehensive Toxicology: Renal Toxicology. Oxford, UK: Elsevier; 2010; 197-211.
Pénard N, Counihan S, D'Arcy S, Rapcan V, Reilly R, Robertson I. Investigating Speech as a Source of Biomarkers for Changes in Cognition, Executive Function and Mood.
Kaufmann SHE. Biomarkers and Vaccines across Borders. AAAS Annual Meeting. Washington, USA (2011).
Biomarker - Visualsonics Inc. website. Available at: www.visualsonics.com/biomarker-development. (Accessed on: October 10, 2011)
Radpour R. Epigenetic and genomic biomarker discovery in breast cancer. PhD Thesis, University of Basel, Basel, Switzerland, July 2011.
As a service, the Publishers can provide each author a certain number of relevant patents to assist them in writing their article. All patent application references will be provided by the author and will be published as it is.
All inventors' names of the patents must be stated with its title, publication number and the year of publication. For example: Han, X. Lipid profile as a biomarker for early detection of neurological disorders. US8026099 (
Citation of patents will be according to the international convention as follows:
Campbell, T., Helms, R.W., Tomasko, L. A system for predicting future health. WO9835609 (
Morimoto, A., Deprimo, S., O'Farrell, A.-M., Smolich, B.D., Manning, W.C., Walter, S.A., Schilling, J. W.J., Cherrington, J. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals. WO03097854 (
Guerrero-Preston, R.E., Sidransky, D., Brebi-Mieville, P. Hypermethylation biomarkers for detection of cervical cancer. WO2011112901 (
Huyn, N.Q. Methods for efficiently mining broad data sets for biological markers. US20020095260 (
Dhib-Jalbut, S. Predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis. US20110230413 (
Al-Bayati, M.A.S. Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications. US5686237 (
Yip, T.T.C., Cho, C.S., Au, S.K., Yip, T.-T., Yip, C., Yip, V. Serum biomarkers in lung cancer. US8014952 (
Allard, W.J. Tumor marker panel for the detection of breast cancer recurrence. EP072766 (
Davies, H.A., McGuire, J., Simonsen, A.H., Blennow, K., Podust, V. Biomarkers for Alzheimer's disease. EP2369348 (
Some important points to remember:
Punctuation should be properly applied as mentioned in the examples given above.
Superscripts in the in-text citations and reference section should be avoided.
Abstracts, unpublished data and personal communications (which can only be included if prior permission has been obtained) should not be given in the references section. The details may however appear in the footnotes.
The authors are encouraged to use a recent version of EndNote (version 5 and above) or Reference Manager (version 10) when formatting their reference list, as this allows references to be automatically extracted.
Data tables should be submitted in Microsoft Word table format.
Each table should include an explanatory title/caption with respect to the details discussed in the table. Detailed legends may then follow.
Table number in bold font
Tables should be embedded in the text exactly according to their appropriate placement in the submitted manuscript.
Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell are displayed as black lines.
Tables should be numbered in Arabic numerals sequentially in order of their citation in the body of the text.
If a reference is cited in both the table and text, please insert a lettered footnote in the table to refer to the numbered reference in the text.
Tabular data provided as additional files can be submitted as an MS Excel spreadsheet.
All authors must strictly follow the guidelines below for preparing illustrations for publication in
Illustrations should be provided as separate files, embedded in the text file, and must be numbered consecutively in the order of their appearance. Each figure should include only a single illustration which should be cropped to minimize the amount of space occupied by the illustration.
If a figure is in separate parts, all parts of the figure must be provided in a single composite illustration file.
Photographs should be provided with a scale bar if appropriate, as well as high-resolution component files.
Line Art image type is normally an image based on lines and text. It does not contain tonal or shaded areas. The preferred file format should be TIFF or EPS, with the color mode being Monochrome 1-bit or RGB, in a resolution of 900-1200 dpi.
Halftone image type is a continuous tone photograph containing no text. It should have the preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of 300 dpi.
Combination image type is an image containing halftone , text or line art elements. It should have the preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of 500-900 dpi.
Illustrations may be submitted in the following file formats:
Bentham Science does not process figures submitted in GIF format.
For TIFF or EPS figures with considerably large file size restricting the file size in online submissions is advisable. Authors may therefore convert to JPEG format before submission as this results in significantly reduced file size and upload time, while retaining acceptable quality. JPEG is a ‘lossy’ format. However, in order to maintain acceptable image quality, it is recommended that JPEG files are saved at High or Maximum quality.
Zipit or Stuffit tools should not be used to compress files prior to submission as the resulting compression through these tools is always negligible.
Please refrain from supplying:
Graphics embedded in word processor (spreadsheet, presentation) document.
Optimized files optimized for screen use (like GIF, BMP, PICT, WPG) because of the low resolution.
Files with too low a resolution.
Graphics that are disproportionately large for the content.
There are many software packages, many of them freeware or shareware, capable of converting to and from different graphics formats, including PNG.
General tools for image conversion include Graphic Converter on the Macintosh, Paint Shop Pro, for Windows, and ImageMagick, available on Macintosh, Windows and UNIX platforms.
Bitmap images (
The cost for each individual page of color figures/plates/illustrations is
Color figures should be supplied in CMYK and not RGB colors.
Chemical structures must be prepared in ChemDraw (CDX) and provided as separate file.
[As according to the ACS style sheet]
Chain angle
120& #x00B0;
Bond spacing
18% of width
Fixed length
14.4 pt (0.500cm, 0.2in)
Bold width
2.0 pt (0.071cm, 0.0278in)
Line width
0.6 pt (0.021cm, 0.0084in)
Margin width
1.6 pt (0.096cm)
Hash spacing
2.5 pt (0.088cm, 0.0347in)
Font
Times New Roman
Size
8 pt
Units
points
Tolerances
3 pixels
Paper
US letter
Scale
100%
We do encourage to append supportive material, for example a PowerPoint file containing information about the study, a PowerPoint file containing additional screenshots, a MS word, RTF, or PDF document showing the original instrument(s) used, a video, or the original data (SAS/SPSS files, Excel files, Access Db files
Supportive/Supplementary Material intended for publication must be numbered and referred to in the manuscript
Any additional files will be linked to the final published article in the form supplied by the author, but will not be displayed within the paper. They will be made available in exactly the same form as originally provided
Authors must clearly indicate if these files are not for publication but meant for the reviewers'/editors' perusal only.
Permission to Reuse Bentham Content
Bentham Science has collaborated with the Copyright Clearance Center to meet our customer’s licensing, besides rights & permission needs.
The Copyright Clearance Center’s RightsLink® service makes it faster and easier to secure permission from Bentham Science’s journal titles. Visit Journals by Title and locate the desired content. Then go to the article’s abstract and click on “Rights and Permissions” to open the RightsLink’s page. If authors can't find the content they are looking for or can't get the rights they need, please contact us at [email protected]
Third-Party Permissions
Authors are responsible for managing the inclusion of third-party content as an author/editor of a work. We refer to 'third party content' as any work that authors haven't developed themselves and have copied or adapted from other sources. Text, figures, photographs, tables, screenshots, and other items may be included.
Unless the figure is in the public domain (copyright-free) or permitted for use under Creative Commons or other open licences, the author must get permission from the copyright holder(s).
Published/reproduced material should not be included unless written permission has been obtained from the copyright holder, which should be forwarded to the Editorial Office in case of acceptance of the article for publication.
Articles are licensed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) (https://creativecommons.org/licenses/by/4.0/legalcode), which permits unrestricted distribution and reproduction in any medium, as long as the work is properly credited/attributed. For more details, please visit Open Access Policy
All manuscripts submitted for publication will be immediately subjected to peer-reviewing, usually in consultation with the members of the Editorial Advisory Board and a number of external referees. Authors may, however, provide in their Copyright Letter the contact details (including e-mail addresses) of four potential peer reviewers for their paper. Any peer reviewers suggested should not have recently published with any of the authors of the submitted manuscript and should not be members of the same research institution.
All papers submitted for publication are immediately subjected to editorial scrutiny, usually in consultation with members of the journal Editorial Advisory Board and outside independent reviewers. Every effort will be made to peer review submitted papers quickly. Papers which are delayed by authors in revision for more than 30 days will have to be re-submitted as a new submission. Papers accepted for publication are typeset and proofs are dispatched to authors for any corrections prior to final publication.
No page charges will be levied to the authors.
Authors should seek professional assistance for the correction of grammatical, scientific, and typographical errors before submission of the revised version of the article for publication.
You may use the professional editing services of our nominated English Language editing organizations TopEdit or Eureka Science.
Please note that we accept a language certificate, only from one of the above two language editing organizations.
영문 오타가 많은 원고는 출판되지 않을 것입니다. 영문 오타를 없애겠다는 조건으로 받은 원고는 영어 편집 전문회사인 유럽 공동 기술개발 기구로부터 가격 견적서가 보내 질 것입니다. 영어 작문에 어려움이 있는 비영어권 국가의 저자들은 원고를 학술지에 제출하기 전에 영어 편집회사와 접촉할 것을 권합니다. 영어 편집 견적서를 받기 위해서 교정될 원고의 단어수를 적은 메일을 유럽 공동 기술개발 기구 메일인 [email protected] 로 보내시기 바랍니다.
含有很多英文印刷错误的提交稿将不予发表。接受发表的稿件其英文写作应是正确的；专业的语言编辑公司（尤里卡科学，可对稿件的英文润色提供报价。建议非英语国家、且英文写作欠佳的作者在投稿前先与语言编辑公司联系。请与尤里卡科学联系 [email protected].
Les manuscrits soumis avec plusieurs erreurs typographiques en Anglais ne seront pas publiés en l’état. Les manuscrits sont acceptés pour publication à la condition que l'anglais utilisé soit corrigé après la soumission et seront envoyés pour examen à Eureka Science, une société d'édition de langue professionnelle. Les auteurs en provenance de pays où la langue est différente de l'anglais et qui ont de médiocres compétences en anglais écrit, sont priés de contacter la société d'édition de langue avant de soumettre leur manuscrit à la revue. Merci de contacter Eureka Science à [email protected] pour un devis en indiquant le nombre total de mot de l’article à éditer.
Authors will receive page proofs of their accepted paper before publications. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within
The corresponding author will be solely responsible for ensuring that the revised version of the manuscript incorporating all the submitted corrections receives the approval of all the co-authors of the manuscript.
Printed reprints and e-prints may be ordered from the Publisher prior to publication of the article. First named authors may also order a personal online subscription of the journal at 50% off the normal subscription rate by contacting the subscription department at e-mail: [email protected].
Bentham Science also offers authors the choice of “Open Access Plus (Gold Open Access)” publication of articles at a fee of US$ 890 per article. This paid service allows for articles to be disseminated to a much wider audience, on the terms of the Creative Commons CC BY-NC-ND (Attribution-NonCommercial-NoDerivs) Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/). Authors are asked to indicate whether or not they wish to pay to have their article made more widely available on this “Open Access Plus (Gold Open Access)” basis. Where an author does not opt-in to this paid service, then the author’s article will be published only on Bentham Science’s standard subscription-based access, at no additional cost to the author.
All editors, board members and those authors who have contributed more than two articles in Bentham Science publications are entitled to a
For more information please contact us at e-mail: [email protected]
Authors who publish in
By signing the Copyright Letter the authors retain the rights of self-archiving. Following are the important features of self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites, their institution’s repositories or any non-commercial repository for personal use, internal institutional use or for permitted scholarly posting.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution’s repository or any non-commercial repository such as PMC, arXiv after
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published version of manuscripts in an institutional repository after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts.
The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS (GOLD OPEN ACCESS) category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website.
The text of every submitted manuscript is checked by using the Content Tracking mode in iThenticate. The Content Tracking mode ensures that manuscripts with an overall low percentage similarity (but which may have a higher similarity from a single source) are not overlooked. If the similarity level is significantly high, then the manuscript is returned to the author for paraphrasing the text and citing the original source of the copied material.
It is important to mention that the text taken from different sources with an overall low similarity percentage will be considered as a plagiarized content if the majority of the article is a combination of copied material.
There may be some manuscripts with an overall low similarity percentage, but a higher percentage from a single source. A manuscript may have less than 20% overall similarity but there may be 15% similar text taken from a single article. The similarity index in such cases is higher than the approved limit for a single source. Authors are advised to thoroughly rephrase the similar text and properly cite the original source to avoid plagiarism and copyright violation.
We all know that scholarly manuscripts are written after a thorough review of previously published articles. It is therefore, not easy to draw a clear boundary between legitimate representation and plagiarism. However, the following important features can assist in identifying different kinds of plagiarized content. These are:
Reproduction of others words, sentences, ideas or findings as one’s own without proper acknowledgement.
Text recycling, also known as self-plagiarism. It is an author’s use of a previous publication in another paper without proper citation and acknowledgment of the original source.
Paraphrasing poorly: Copying complete paragraphs and modifying a few words without changing the structure of original sentences or changing the sentence structure but not the words.
Verbatim copying of text without putting quotation marks and not acknowledging the work of the original author.
Properly citing a work but poorly paraphrasing the original text is considered as unintentional plagiarism. Similarly, manuscripts with language somewhere between paraphrasing and quoting are not acceptable. Authors should either paraphrase properly or quote and in both cases, cite the original source.
Higher similarity in the abstract, introduction, materials and methods, and discussion and conclusion sections indicates that the manuscript may contain plagiarized text. Authors can easily explain these parts of the manuscript in many ways. However, technical terms and sometimes standard procedures cannot be rephrased; therefore Editors must review these sections carefully before making a decision.
Published manuscripts which are found to contain plagiarized text are retracted from the journal website after careful investigation and approval by the Editor-in-Chief of the journal. A ‘Retraction Note’ as well as a link to the original article is published on the electronic version of the plagiarized manuscript and an addendum with retraction notification in the journal concerned.
For further details, please visit: https://www.eurekaselect.com/research-misconduct
Articles appearing in E-Pub Ahead-of-Schedule sections have been peer-reviewed and accepted for publication in this journal and posted online before scheduled publication. Articles appearing here may contain statements, opinions, and information that have errors in facts, figures or interpretation. Accordingly,
